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AUDIT UPDATE
Clinical management and outcome of refractory
asthma in the UK from the British Thoracic Society
Difficult Asthma Registry
Joan Sweeney,1 Chris E Brightling,2 Andrew Menzies-Gow,3 Robert Niven,4
Chris C Patterson,5 Liam G Heaney,1 on behalf of the British Thoracic Society Difficult
Asthma Network
ABSTRACT
Refractory asthma represents a significant unmet clinical
need. Data from a national online registry audited clinical
outcome in 349 adults with refractory asthma from four
UK specialist centres in the British Thoracic Society
Difficult Asthma Network. At follow-up, lung function
improved, with a reduction in important healthcare
outcomes, specifically hospital admission, unscheduled
healthcare visits and rescue courses of oral steroids. The
most frequent therapeutic intervention was maintenance
oral corticosteroids and most steroid sparing agents
(apart from omalizumab) demonstrated minimal steroid
sparing benefit. A significant unmet clinical need remains
in this group, specifically a requirement for therapies
which reduce systemic steroid exposure.
BACKGROUND
We have previously published the clinical features
of a well characterised group of patients with
refractory asthma from specialist UK centres oper-
ating established dedicated multidisciplinary
assessment protocols and identiﬁed important
differences between patient groups in individual
centres.1 Using the national online registry, we
have now audited clinical outcome in 349 of the
382 patients in the original cohort (median follow-
up 3.1 years, IQR 1.9e5.5).
RESULTS
There were no differences in baseline demograph-
ical variables in the follow-up cohort compared
with those lost to follow-up (online supplementary
appendix 1).
At follow-up, there was a signiﬁcant improve-
ment in lung function and a reduction in important
healthcare outcomes, speciﬁcally hospital admis-
sion, unscheduled healthcare visits and rescue
courses of oral steroids (table 1). These effects were
generally consistent across clinical centres though
unscheduled visits were signiﬁcantly increased in
Manchester (online supplementary appendix 2),
reﬂecting the delivery of care at this centre where
patients with an increase in symptoms are
encouraged to attend the hospital centre.
There was no signiﬁcant change in dose of
inhaled steroid or reported reliever medication use
but there was a signiﬁcant increase in the number
of patients prescribed maintenance oral steroids
(from 146 (42%) to 199 (57%)). Only 25 patients
(7%) successfully withdrew oral steroids, whereas
78 (22%) were moved onto maintenance oral
steroids. There was no signiﬁcant difference in the
dose of oral steroids from baseline to follow-up
(16.2610.4 mg baseline, 15.3612.8 follow-up).
Consistent with this widespread use of oral
steroids, there was a signiﬁcant reduction in blood
eosinophils and increase in body mass index (BMI)
(table 1). There was a non-signiﬁcant trend for the
subjects on oral steroids at follow-up to have
a higher BMI compared with those not on oral
steroids (subjects not on oral steroids 29.567.0,
subjects on oral steroids 30.966.0, p¼0.07).
However, BMI also increased in patients not on
maintenance steroids at follow-up (baseline BMI
28.366.8 vs follow-up BMI 29.266.9, p<0.001); in
this group median rescue steroid exposure was one
course of steroids in the preceding 12 months (IQR
0e3).
While blood eosinophils decreased, exhaled nitric
oxide paradoxically increased. Because paired frac-
tional exhaled nitric oxide (FeNO) data were only
available in a limited number of patients, we
examined paired blood eosinophil counts in this
subgroup (n¼75). The paradoxical fall in blood
eosinophils and rise in FeNO were also apparent in
this group (eosinophil count in subjects with paired
FeNO measurements  baseline eosinophils 3 109/
litre, median 0.33 (IQR 0.12e0.54) vs follow-up
eosinophils, median 0.24 (IQR 0.1e0.4), p¼0.001;
and baseline FeNO ppb, 47 (IQR 22e69) vs follow-
up FeNO, 88 (IQR 76e99), p<0.001).
Steroid sparing strategies (online supplementary
appendix 3) and additional therapeutic strategies
(online supplementary appendix 4) utilised in this
refractory population are shown by centre; thera-
peutic success was deﬁned by the treating clinician.
In general, small numbers of patients were tried on
steroid-sparing strategies and few were recorded as
clinically beneﬁcial. The use of other interventions
was infrequent and variable across clinical centres.
Responders to omalizumab (37 of 59 (63%) based
on criteria for the National Health Service
Outcomes Drug Reimbursement Scheme, http://
guidance.nice.org.uk/TA133/Guidance/doc/English)
were more likely to be off oral steroids at clinical
follow-up (17 of 37 vs 4 of 22, p¼0.031, OR 3.8
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journal online (http://thorax.bmj.
com/content/67/8.toc).
1Centre for Infection and
Immunity, Queen’s University of
Belfast, Belfast, UK
2Institute for Lung Health,
Department of Infection,
Inflammation and Immunity,
University of Leicester,
Leicester, UK
3Royal Brompton and Harefield
NHS Foundation Trust, London,
UK
4The University of Manchester
(MAHSC) and University
Hospital of South Manchester,
UK
5Centre for Public Health,
Queen’s University of Belfast,
Belfast, UK
Correspondence to
Professor Liam G Heaney,
Centre for Infection and
Immunity, Queen’s University of
Belfast, Level 8, Belfast City
Hospital, Lisburn Road, Belfast
BT9 7AB, UK;
l.heaney@qub.ac.uk
Received 6 March 2012
Accepted 30 March 2012
Published Online First
11 May 2012
This paper is freely available
online under the BMJ Journals
unlocked scheme, see http://
thorax.bmj.com/site/about/
unlocked.xhtml
754 Thorax 2012;67:754e756. doi:10.1136/thoraxjnl-2012-201869
Chest clinic
C
h
e
st
c
li
n
ic
 group.bmj.com on May 3, 2013 - Published by thorax.bmj.comDownloaded from 
(95% CI 1.0 to 18.2), c2). Individual responses also support
a steroid-sparing effectdin subjects on maintenance oral steroids
pre omalizumab (n¼28), 9 withdrew oral steroids completely
(baseline dose 20 mg (10e35 mg)), 11 had a steroid dose reduc-
tion (baseline dose 20 mg (15e20 mg), follow-up 13 mg
(10e15 mg), p¼0.003, Wilcoxon signed rank test) and 8 had an
increase in dose (10 mg (7e10 mg), follow-up 12.25 (10e15 mg),
p¼0.027, Wilcoxon signed rank test). Of the other 8 subjects
whose condition responded to omalizumab only 1 progressed to
oral steroids, whereas of those on omalizumab whose condition
did not respond, 18 of 22 were on oral steroids at follow-up
(15 mg (10e25 mg)).
Using logistic regression, baseline predictors of maintenance
oral steroids at follow-up were maintenance oral steroids at
baseline (OR 8.3, 95% CI 4.8 to 14.4), male gender (OR 2.2, 95%
CI 1.3 to 3.7), and rescue steroids in the preceding year (OR 2.3,
95% CI 1.1 to 4.9). At follow-up, 84 of 127 men (66%) compared
with 115 of 222 women (52%) were on maintenance oral
steroids (c2, p<0.01).
DISCUSSION
This audit provides the ﬁrst outcome data on a well charac-
terised cohort of adults with severe refractory asthma. We report
signiﬁcant changes in important healthcare outcomes, particu-
larly reductions in unscheduled visits, hospital admissions and
rescue oral steroids, which taken collectively suggests a reduc-
tion in severe exacerbations. Improvement was also seen in lung
function, but notably daily reliever medication use was not
different, suggesting persistent symptomatic morbidity in this
group. Because of the precise characterisation of this group, we
believe this is due to asthma and not other non-asthma
comorbidities.
As this is an observational clinical registry, we cannot exclude
the possibility that the improvement in healthcare outcomes
simply represents ‘regression to the mean’, since at the time of
referral and initial assessment, patients are likely to be clinically
unwell. However, 60e75% of patients in these centres are
tertiary referrals and had difﬁcult asthma for prolonged periods
prior to assessment, making regression to the mean unlikely to
be the entire explanation for the observed improvement. Even at
baseline, in this severe asthmatic population, hospital admission
rate was relatively low, but unscheduled healthcare contact and
rescue steroid courses were high. With appropriate specialist
management, hospital admission rates were further reduced,
suggesting the economic cost of refractory asthma is unlikely to
be driven by hospital admission.
The commonest therapeutic strategy was initiation of main-
tenance steroids, which is consistent with the reduction in
peripheral blood eosinophils and the reduction in rescue oral
steroid courses. The dissociation between FeNO, clinical
outcome and blood eosinophilia is consistent with other data,
which have shown that FeNO-based strategies have not been
able to reduce exacerbation rates.2 In a recent oral steroid
tapering study, which included FeNO as part of the steroid
reduction algorithm, weekly Asthma Control Questionnaire and
forced expiratory volume in 1 s measurement were the major
drivers of steroid reduction, with minimal contribution from
daily FeNO.3 Collectively, these data question whether FeNO is
useful in adjusting steroid dose in patients on maintenance or
frequent bursts of oral steroids.
The increase in BMI is also consistent with more steroid
exposure, but BMI also increased in subjects not on maintenance
oral steroids at follow-up. This latter group remained on high-
dose inhaled steroids but rescue steroid exposure in the
preceding 12 months was relatively low (median 1, IQR 0e3),
suggesting that BMI increase is not exclusively related to oral
steroid exposure in this population, and reduced exercise
capacity due to persistent asthma may be relevant.
The best predictor of being on oral steroids was being on them
at referral, which might initially suggest that specialist services
have a minimal effect on maintenance steroid exposure in this
patient population. However, this cohort of patients had well
phenotyped refractory asthma after detailed systematic evalua-
tion and issues such as incorrect diagnosis, comorbidities and
non-adherence have been identiﬁed and these subjects excluded.
One of the major advantages and beneﬁts of a specialist difﬁcult
asthma service is ensuring precise patient characterisation and
appropriateness of high-dose asthma therapy in subjects with
refractory asthma.4
It is unclear why a greater proportion of men were more likely
to be on oral steroids at follow-up. Cohorts of difﬁcult and
refractory asthma typically include more women,4 5 but these
data suggest that the requirement for oral steroids, which might
be interpreted as one index of severity, is less common in
women. Frequency of rescue steroids is also predictive of
progression as this identiﬁes someone with steroid-responsive
disease prone to exacerbation despite high-dose inhaled therapy.
Steroid-sparing strategies (cyclosporin, methotrexate, azathio-
prine, mycophenolate) are used variably across centres, with
limited clinical success. The low trial rate in some centres reﬂects
the potential side effects of these agents, but additionally our
observational data also suggest that the success rate of the most
commonly used agents (methotrexate and cyclosporin) is low,
which is consistent with the conclusions of recent Cochrane
reviews of both methotrexate and cyclosporin.6 7
The only additional therapeutic intervention that demon-
strated a steroid-sparing effect was omalizumab. In subjects
who received a clinical trial of omalizumab, the overall response
rate was 63% and 20 (71%) of the 28 on oral steroids either
withdrew or signiﬁcantly reduced their oral steroid dose.
In summary, this audit demonstrates improved outcomes
with reduced exacerbation rates and healthcare utilisation, but
at the cost of increased numbers of subjects on systemic steroids.
Table 1 Lung function and healthcare outcomes for cohort
Baseline Follow-up p Value
Pre-bronchodilator FEV1 %
predicted (259)
66.4623.7 72.7626.8 <0.001
Pre-bronchodilator FVC %
predicted (242)
82.7620.3 86.5621.5 0.002
Post-bronchodilator FEV1 %
predicted (77)
79.2621.5 77.6630.7 0.61
Post-bronchodilator FVC %
predicted (72)
90.66 19.8 86.36 25.9 0.08
Rescue oral steroids in
previous 12 months (302)
4 (2e6) 2 (0e4) <0.001
Hospital admissions in
previous 12 months (324)
0 (0e2) 0 (0e1) <0.01
Unscheduled visits in
previous 12 months (315)
4 (2e6) 2 (0e6) <0.05
Inhaled steroid dose, BDP
equivalent (327)
2000 (1000e2000) 2000 (1200e2000) 0.80
Average daily SABA use (205) 6 (4e9) 8 (4e10) 0.058
Blood eosinophils (206) 0.33 (0.11e0.60) 0.20 (0.09e0.43) <0.001
FeNO (112) 40 (18e69) 89 (77e102) <0.001
Body mass index 29.266.5 30.266.4 <0.001
Group data (mean6SD or median (IQR)) for all subjects are presented in column 1 followed
by data for individual centres. Comparisons were made using paired samples t tests or
Wilcoxon signed rank tests; significance was taken as p<0.05.
BDP, beclometasone dipropionate; FeNO, fractional expiratory nitric oxide; FEV1, forced
expiratory volume in 1 s; FVC, forced vital capacity; SABA, short-acting b agonist.
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Steroid-sparing therapies are infrequently used and are only
modestly successful in routine clinical practice. In patients who
respond to omalizumab, there is the suggestion of a signiﬁcant
steroid-sparing effect in some but not all subjects. There remains
a signiﬁcant unmet clinical need in this group and speciﬁcally
a requirement for therapies which reduce systemic steroid
exposure.
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